Category: Research

Month: 01 Oct 2014

Issue: not yet available

Results of small cell study suggests aflibercept and bevacizumab may impair wound healing capability of porcine RPE cells

Research, based at the Department of Ophthalmology at the University of Kiel, Germany, has indicated that aflibercept and bevacizumab may interfere with the physiology of RPE cells. The in-vitro lab-based study assessed the impact of aflibercept and bevacizumab in a primary porcine RPE cell system and results suggested that when clinically relevant concentrations were used, aflibercept and bevacizumab displayed a statistically significant effect on wound healing compared with control (control 87.3±8.4% closure, aflibercept 500 mg/mL 70.3±10.3% closure, p<0.01; bevacizumab 250 mg/mL 80.7±6.8% closure, p<0.05).

Back to previous

Related News

Gearoid Tuohy

editor

by Dr. Gearóid Tuohy   Dear EURETINA Members,   A very warm welcome to the December 4th, 2017 edition of EURETINA’s web-based digital magazine, “EURETINA Brief”. EURETINA are delighted to continue our delivery of up-to-date summary briefs on a range of topics of interest to retinal clinicians, specialists and researchers across Europe. This resource is […]